日本語フィールド
著者：*Kazuomi Kario, Julio A Chirinos, Raymond R Townsend, Michael A Weber, Angelo Scuteri, Alberto Avolio, Satoshi Hoshide, Tomoyuki Kabutoya, Hirofumi Tomiyama, Koichi Node, Mitsuru Ohishi, Sadayoshi Ito, Takuya Kishi, Hiromi Rakugi, Yan Li, Chen-Huan Chen, Jeong Bae Park, Ji-Guang Wang題名：Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia 発表情報：Prog Cardiovasc Dis. 巻: 63 号: 1 ページ: 22-32キーワード：概要：Hypertension (HTN) is an important risk factor for cardiovascular disease (CVD) but the association between HTN and CVD cannot be explained by average blood pressure (BP) alone. BP variability (BPV) is another important factor, along with the effects of HTN on the vasculature. The concept of systemic hemodynamic atherothrombotic syndrome (SHATS) has been proposed, describing an age-related and synergistic vicious cycle of hemodynamic stress and vascular disease. The importance of SHATS is based on the assumption that the assessment of BPV and arterial disease is likely to provide an effective opportunity to intervene early to reduce progression to HTN in younger patients or to CVD events and organ damage in older patients. In addition to providing an overview of current evidence for the mechanisms and clinical data related to SHATS, this article proposes a new SHATS score for use to diagnose and assess the severity of SHATS. The score includes two components - a BP score and a vascular score - which are multiplied to generate the SHATS score. This reflects the synergistic, rather than additive, effects of BP and vascular disease on target organ damage and CVD events. Although it requires refinement and validation in future studies, early detection of SHATS using tools such as the proposed score, combined with population-based stratification and technology-based anticipation medicine incorporating real-time individual data, has the potential to contribute to meaningful reductions in rates of CVD events and target organ damage. 抄録：英語フィールド
Author：*Kazuomi Kario, Julio A Chirinos, Raymond R Townsend, Michael A Weber, Angelo Scuteri, Alberto Avolio, Satoshi Hoshide, Tomoyuki Kabutoya, Hirofumi Tomiyama, Koichi Node, Mitsuru Ohishi, Sadayoshi Ito, Takuya Kishi, Hiromi Rakugi, Yan Li, Chen-Huan Chen, Jeong Bae Park, Ji-Guang WangTitle：Systemic hemodynamic atherothrombotic syndrome (SHATS) - Coupling vascular disease and blood pressure variability: Proposed concept from pulse of Asia Announcement information:Prog Cardiovasc Dis. Vol: 63 Issue: 1 Page: 22-32An abstract：Hypertension (HTN) is an important risk factor for cardiovascular disease (CVD) but the association between HTN and CVD cannot be explained by average blood pressure (BP) alone. BP variability (BPV) is another important factor, along with the effects of HTN on the vasculature. The concept of systemic hemodynamic atherothrombotic syndrome (SHATS) has been proposed, describing an age-related and synergistic vicious cycle of hemodynamic stress and vascular disease. The importance of SHATS is based on the assumption that the assessment of BPV and arterial disease is likely to provide an effective opportunity to intervene early to reduce progression to HTN in younger patients or to CVD events and organ damage in older patients. In addition to providing an overview of current evidence for the mechanisms and clinical data related to SHATS, this article proposes a new SHATS score for use to diagnose and assess the severity of SHATS. The score includes two components - a BP score and a vascular score - which are multiplied to generate the SHATS score. This reflects the synergistic, rather than additive, effects of BP and vascular disease on target organ damage and CVD events. Although it requires refinement and validation in future studies, early detection of SHATS using tools such as the proposed score, combined with population-based stratification and technology-based anticipation medicine incorporating real-time individual data, has the potential to contribute to meaningful reductions in rates of CVD events and target organ damage. 